Literature DB >> 19672600

A comparison of performance of anti-cyclic citrullinated peptide 2 and citrullinated protein antibodies in the diagnosis of rheumatoid arthritis in Iranian patients.

Elham Aflaky1, Saeedeh Shenavandeh, Mohammad Javad Ashraf.   

Abstract

Antibodies to citrullinated proteins and rheumatoid factor (RF) are widely used in patients with rheumatoid arthritis (RA) and the antibodies to citrullinated proteins appear to be the most specific markers of the disease. The objective was to compare the diagnostic performance of the anti-cyclic citrullinated peptide 2 (anti-CCP2) and citrullinated protein Antibodies (CPA) with RF in the diagnosis of RA. Serum samples of 139 patients with RA and 131 patients with other rheumatic diseases were checked for anti-CCP2, CPA uses citrullinated recombinant rat filaggrin as the antigen assay, and RF. The specificity, sensitivity, and receiver operating characteristic (ROC) of tests were then compared. The sensitivity of anti-CCP2, CPA, and RF were 82.7, 83.5, and 61.5%, respectively. The specificities of the tests were 91.2, 78.6, and 90.5%, respectively. The area under ROC curves for the tests were 0.925, 0.890, and 0.847, respectively. Exclusion of overlaps was associated with improved specificity for CPA but no change in the specificity of RF and anti-CCP. The sensitivity of anti-CCP2, CPA, and RF were 66.7, 77.8, and 51.9% for patients with early RA, respectively. The findings of the present study indicate that anti-CCP2 might be of a better diagnostic value for the diagnosis of RA. They also showed that CPA and in the second place anti-CCP2 were useful in the diagnosis of early RA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672600     DOI: 10.1007/s00296-009-0980-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.

Authors:  J van Aken; L R Lard; S le Cessie; J M W Hazes; F C Breedveld; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

2.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

3.  Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

Authors:  L Vasiliauskiene; A Wiik; M Høier-Madsen
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

4.  Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors.

Authors:  S Bas; T V Perneger; E Kunzle; T L Vischer
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

5.  Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis.

Authors:  N Bizzaro; G Mazzanti; E Tonutti; D Villalta; R Tozzoli
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

6.  A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis.

Authors:  F A van Gaalen; H Visser; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

7.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

8.  Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis.

Authors:  Suk Woo Choi; Mi Kyoung Lim; Dong Hyuk Shin; Jeong Jin Park; Seung Cheol Shim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  Clinical utility of the anti-CCP assay in patients with rheumatic diseases.

Authors:  D M Lee; P H Schur
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

10.  Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.

Authors:  S Dubucquoi; E Solau-Gervais; D Lefranc; L Marguerie; J Sibilia; J Goetz; V Dutoit; A-L Fauchais; E Hachulla; R-M Flipo; L Prin
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

View more
  3 in total

1.  Feasibility study of semi-automated measurements of finger joint space widths.

Authors:  Alexander Pfeil; Julia Sommerfeld; Rosemarie Fröber; Gabriele Lehmann; Ansgar Malich; Andreas Hansch; Gunter Wolf; Joachim Böttcher
Journal:  Rheumatol Int       Date:  2010-04-17       Impact factor: 2.631

2.  Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.

Authors:  Jamileh Moghimi; Raheb Ghorbani; Farnaz Hasani; Mehrdad Sheikhvatan
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

3.  The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis.

Authors:  Bridget Hodkinson; Pieter W A Meyer; Eustasius Musenge; Mahmood M T Ally; Ahmed A Wadee; Ronald Anderson; Mohammed Tikly
Journal:  Clin Rheumatol       Date:  2010-02-02       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.